{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:24:31Z","timestamp":1793499871218,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Blood phosphorylated tau 217\u00a0(p-tau217) accurately detects Alzheimer\u2019s disease (AD) pathology but is also elevated in amyotrophic lateral sclerosis (ALS), likely reflecting peripheral (big) tau released from muscle. Assays selectively measuring brain-derived (BD-) tau and BD-p-tau217 are therefore needed. We analysed serum BD-tau and p-tau217 in ALS (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009139), AD (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009101) and controls (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200975) using direct immunoassays and after BD-Tau immunoprecipitation (BD-Tau-IP), and tau species in brain (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200916), spinal cord (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200911) and muscle (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200910) by targeted mass spectrometry. With the direct immunoassays, BD-tau and p-tau217 were increased in AD and ALS versus controls. After BD-Tau-IP, BD-tau and BD-p-tau217 were elevated in AD only, improving diagnostic accuracy. Mass spectrometry revealed a central-to-peripheral shift from BD-tau to big tau predominance, with exclusively big p-tau217 detected\u00a0in muscle. Selective detection of BD-tau species improves the\u00a0specificity of blood AD biomarkers by reducing peripheral tau confounding.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-78390-3","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:02:40Z","timestamp":1792659760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tau isoform mapping across tissues and biofluids reveals a signature distinguishing Alzheimer\u2019s disease from amyotrophic lateral sclerosis"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0631-8506","authenticated-orcid":false,"given":"Samir","family":"Abu-Rumeileh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5122-2477","authenticated-orcid":false,"given":"Henning","family":"Gro\u00dfkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Guthknecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0089-4473","authenticated-orcid":false,"given":"Alexander","family":"Mensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Osterloh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-6614","authenticated-orcid":false,"given":"Antonia","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Stapf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Krippner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7652-7023","authenticated-orcid":false,"given":"Patrick","family":"Oeckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Stoltenburg-Didinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Maranzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Steinacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Weise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"D\u2019Anna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-9032","authenticated-orcid":false,"given":"Hans-Wolfgang","family":"Klafki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-5330","authenticated-orcid":false,"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-3854","authenticated-orcid":false,"given":"Vincenzo","family":"Silani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1494-0813","authenticated-orcid":false,"given":"Lutz","family":"Froelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-7426","authenticated-orcid":false,"given":"Nicola","family":"Ticozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9009-2356","authenticated-orcid":false,"given":"Lucrezia","family":"Hausner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-1075","authenticated-orcid":false,"given":"Dietmar Rudolf","family":"Thal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen Hans","family":"Weishaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolf","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4273-4267","authenticated-orcid":false,"given":"Markus","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"78390_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 https:\/\/doi.org\/10.1056\/NEJMoa2212948 (2023).","journal-title":"N. Engl. J. Med."},{"key":"78390_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70208","volume":"21","author":"S Janelidze","year":"2025","unstructured":"Janelidze, S. et al. A comparison of p-tau assays for the specificity to detect tau changes in Alzheimer\u2019s disease. Alzheimers Dement 21, e70208 https:\/\/doi.org\/10.1002\/alz.70208 (2025).","journal-title":"Alzheimers Dement"},{"key":"78390_CR3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/S1474-4422(25)00227-3","volume":"24","author":"J Therriault","year":"2025","unstructured":"Therriault, J. et al. Blood phosphorylated tau for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 24, 740\u2013752 https:\/\/doi.org\/10.1016\/S1474-4422(25)00227-3 (2025).","journal-title":"Lancet Neurol."},{"key":"78390_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14508","volume":"21","author":"NJ Ashton","year":"2025","unstructured":"Ashton, N. J. et al. The Alzheimer\u2019s Association Global Biomarker Standardization Consortium plasma phospho-tau Round Robin study. Alzheimers Dement 21, e14508 https:\/\/doi.org\/10.1002\/alz.14508 (2025).","journal-title":"Alzheimers Dement"},{"key":"78390_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s40478-025-02064-2","volume":"13","author":"D Bali","year":"2025","unstructured":"Bali, D. et al. Comparison of plasma ALZpath p-Tau217 with Lilly p-Tau217 and p-Tau181 in a neuropathological cohort. Acta Neuropathol. Commun. 13, 144 https:\/\/doi.org\/10.1186\/s40478-025-02064-2 (2025).","journal-title":"Acta Neuropathol. Commun."},{"key":"78390_CR6","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/brain\/awac407","volume":"146","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz, F. et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer\u2019s disease-type neurodegeneration. Brain 146, 1152\u20131165 https:\/\/doi.org\/10.1093\/brain\/awac407 (2023).","journal-title":"Brain"},{"key":"78390_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47286-5","volume":"15","author":"F Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz, F. et al. Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer\u2019s disease. Nat. Commun. 15, 2908 https:\/\/doi.org\/10.1038\/s41467-024-47286-5 (2024).","journal-title":"Nat. Commun."},{"key":"78390_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57144-7","volume":"16","author":"S Abu-Rumeileh","year":"2025","unstructured":"Abu-Rumeileh, S. et al. Phosphorylated tau 181 and 217 are elevated in serum and muscle of patients with amyotrophic lateral sclerosis. Nat. Commun. 16, 2019 https:\/\/doi.org\/10.1038\/s41467-025-57144-7 (2025).","journal-title":"Nat. Commun."},{"key":"78390_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/acn3.70001","volume":"12","author":"EV Thomas","year":"2025","unstructured":"Thomas, E. V. et al. ALS plasma biomarkers reveal neurofilament and pTau correlate with disease onset and progression. Ann. Clin. Transl. Neurol. 12, 714\u2013723 https:\/\/doi.org\/10.1002\/acn3.70001 (2025).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"78390_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.tins.2020.04.007","volume":"43","author":"I Fischer","year":"2020","unstructured":"Fischer, I. & Baas, P. W. Resurrecting the mysteries of big tau. Trends Neurosci 43, 493\u2013504 https:\/\/doi.org\/10.1016\/j.tins.2020.04.007 (2020).","journal-title":"Trends Neurosci"},{"key":"78390_CR11","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1002\/alz.13784","volume":"20","author":"S Buchholz","year":"2024","unstructured":"Buchholz, S. & Zempel, H. The six brain-specific TAU isoforms and their role in Alzheimer\u2019s disease and related neurodegenerative dementia syndromes. Alzheimers Dement 20, 3606\u20133628 https:\/\/doi.org\/10.1002\/alz.13784 (2024).","journal-title":"Alzheimers Dement"},{"key":"78390_CR12","doi-asserted-by":"publisher","unstructured":"Koppisetti, R. K. et al. Distribution of Big Tau Isoforms in the Human Central and Peripheral Nervous System. Ann. Neurol. 100, 709\u2013736\u00a0https:\/\/doi.org\/10.1002\/ana.78300 (2026).","DOI":"10.1002\/ana.78300"},{"key":"78390_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 https:\/\/doi.org\/10.1001\/jama.2020.12134 (2020).","journal-title":"JAMA"},{"key":"78390_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-40271-6","volume":"16","author":"MN Nafash","year":"2026","unstructured":"Nafash, M. N. et al. Plasma brain-derived tau: analytical and clinical validation of the first commercial immunoassay. Sci. Rep. 16, 10124 https:\/\/doi.org\/10.1038\/s41598-026-40271-6 (2026).","journal-title":"Sci. Rep."},{"key":"78390_CR15","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00406-023-01751-2","volume":"275","author":"B Morgado","year":"2025","unstructured":"Morgado, B. et al. Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer\u2019s disease. Eur. Arch. Psychiatry Clin. Neurosci. 275, 2215\u20132227 https:\/\/doi.org\/10.1007\/s00406-023-01751-2 (2025).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"78390_CR16","doi-asserted-by":"publisher","unstructured":"Morgado, B. et al. Evaluation of a fully automated assay for the measurement of plasma pTau217 and a composite score integrating the ratio A\u03b21\u201342\/1\u201340 as biomarkers of Alzheimer\u2019s disease. Eur. Arch. Psychiatry Clin. Neurosci. 276, 2251-2264 https:\/\/doi.org\/10.1007\/s00406-025-02123-8 (2026).","DOI":"10.1007\/s00406-025-02123-8"},{"key":"78390_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14422","volume":"21","author":"GM Bentivenga","year":"2025","unstructured":"Bentivenga, G. M. et al. Clinical value of novel blood-based tau biomarkers in Creutzfeldt\u2013Jakob disease. Alzheimers Dement 21, e14422 https:\/\/doi.org\/10.1002\/alz.14422 (2025).","journal-title":"Alzheimers Dement"},{"key":"78390_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05767-7","volume":"22","author":"E Agah","year":"2024","unstructured":"Agah, E. et al. CSF and blood levels of neurofilaments, T-tau, P-tau and A\u03b242 in amyotrophic lateral sclerosis: a systematic review and meta-analysis. J. Transl. Med. 22, 953 https:\/\/doi.org\/10.1186\/s12967-024-05767-7 (2024).","journal-title":"J. Transl. Med."},{"key":"78390_CR19","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3233\/JAD-230900","volume":"95","author":"L Barba","year":"2023","unstructured":"Barba, L., Otto, M. & Abu-Rumeileh, S. The underestimated relevance of Alzheimer\u2019s disease copathology in amyotrophic lateral sclerosis. J. Alzheimers Dis. 95, 1401\u20131404 https:\/\/doi.org\/10.3233\/JAD-230900 (2023).","journal-title":"J. Alzheimers Dis."},{"key":"78390_CR20","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/s43587-025-00951-w","volume":"5","author":"L Montoliu-Gaya","year":"2025","unstructured":"Montoliu-Gaya, L. et al. Plasma tau biomarkers for biological staging of Alzheimer\u2019s disease. Nat. Aging 5, 2297\u20132308 https:\/\/doi.org\/10.1038\/s43587-025-00951-w (2025).","journal-title":"Nat. Aging"},{"key":"78390_CR21","unstructured":"Roboscreen. BD-Tau antibody product information. https:\/\/www.roboscreen.com\/index.php?eID=dumpFile&t=f&f=486&token=d83f35c261e96658ae96017c6485afa75380da51 (2024)."},{"key":"78390_CR22","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1212\/WNL.0000000000003293","volume":"87","author":"R Hanewinckel","year":"2016","unstructured":"Hanewinckel, R. et al. Prevalence of polyneuropathy in the general middle-aged and elderly population. Neurology 87, 1892\u20131898 https:\/\/doi.org\/10.1212\/WNL.0000000000003293 (2016).","journal-title":"Neurology"},{"key":"78390_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117054","volume":"417","author":"D Richards","year":"2020","unstructured":"Richards, D., Morren, J. A. & Pioro, E. P. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J. Neurol. Sci. 417, 117054 https:\/\/doi.org\/10.1016\/j.jns.2020.117054 (2020).","journal-title":"J. Neurol. Sci."},{"key":"78390_CR24","doi-asserted-by":"publisher","first-page":"8197","DOI":"10.3390\/jcm14228197","volume":"14","author":"MP Takahashi","year":"2025","unstructured":"Takahashi, M. P. et al. Plasma neurofilament light chain and phosphorylated tau are elevated in myotonic dystrophy type 1. J. Clin. Med. 14, 8197 https:\/\/doi.org\/10.3390\/jcm14228197 (2025).","journal-title":"J. Clin. Med."},{"key":"78390_CR25","doi-asserted-by":"publisher","unstructured":"Kaeser, S. A. et al. Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-026-04272-2 (2026).","DOI":"10.1038\/s41591-026-04272-2"},{"key":"78390_CR26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2536792123","volume":"123","author":"Y Jiang","year":"2026","unstructured":"Jiang, Y. et al. Head-to-head comparison of brain-derived pTau217 and total pTau217 for brain amyloid and tau pathology classification. Proc. Natl. Acad. Sci. USA. 123, e2536792123 https:\/\/doi.org\/10.1073\/pnas.2536792123 (2026).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"78390_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13024-026-00941-5","volume":"21","author":"AN Trelle","year":"2026","unstructured":"Trelle, A. N. et al. Plasma proteomic signatures of preclinical Alzheimer\u2019s disease in clinically unimpaired older adults. Mol. Neurodegener. 21, 31 https:\/\/doi.org\/10.1186\/s13024-026-00941-5 (2026).","journal-title":"Mol. Neurodegener."},{"key":"78390_CR28","doi-asserted-by":"publisher","first-page":"e2321554","DOI":"10.1001\/jamanetworkopen.2023.21554","volume":"6","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz, F. et al. Association of serum brain-derived tau with clinical outcome and longitudinal change in patients with severe traumatic brain injury. JAMA Netw. Open 6, e2321554 https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.21554 (2023).","journal-title":"JAMA Netw. Open"},{"key":"78390_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/joim.20041","volume":"297","author":"F Gonzalez-Ortiz","year":"2025","unstructured":"Gonzalez-Ortiz, F. et al. Plasma brain-derived tau correlates with cerebral infarct volume. J. Intern. Med. 297, 173\u2013185 https:\/\/doi.org\/10.1111\/joim.20041 (2025).","journal-title":"J. Intern. Med."},{"key":"78390_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders \u2014 towards clinical application. Nat. Rev. Neurol. 20, 269\u2013287 https:\/\/doi.org\/10.1038\/s41582-024-00955-x (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"78390_CR31","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/ana.26462","volume":"92","author":"KAQ Cousins","year":"2022","unstructured":"Cousins, K. A. Q. et al. Elevated plasma phosphorylated tau 181 in amyotrophic lateral sclerosis. Ann. Neurol. 92, 807\u2013818 https:\/\/doi.org\/10.1002\/ana.26462 (2022).","journal-title":"Ann. Neurol."},{"key":"78390_CR32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp-2022-330709","volume":"94","author":"V Vacchiano","year":"2023","unstructured":"Vacchiano, V. et al. Elevated plasma p-tau181 levels unrelated to Alzheimer\u2019s disease pathology in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 94, 428\u2013435 https:\/\/doi.org\/10.1136\/jnnp-2022-330709 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"78390_CR33","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1007\/s10072-023-06916-4","volume":"44","author":"F Verde","year":"2023","unstructured":"Verde, F. et al. Phosphorylated tau in plasma could be a biomarker of lower motor neuron impairment in amyotrophic lateral sclerosis. Neurol. Sci. 44, 3697\u20133702 https:\/\/doi.org\/10.1007\/s10072-023-06916-4 (2023).","journal-title":"Neurol. Sci."},{"key":"78390_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70359","author":"T Kawarabayashi","year":"2026","unstructured":"Kawarabayashi, T. et al. Clinical validation of plasma p-217tau in neurological diseases. Ann. Clin. Transl. Neurol. https:\/\/doi.org\/10.1002\/acn3.70359 (2026).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"78390_CR35","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","volume":"80","author":"S Janelidze","year":"2023","unstructured":"Janelidze, S. et al. Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurol. 80, 516\u2013522 https:\/\/doi.org\/10.1001\/jamaneurol.2023.0199 (2023).","journal-title":"JAMA Neurol."},{"key":"78390_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"BR Brooks","year":"2000","unstructured":"Brooks, B. R. et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 293\u2013299 https:\/\/doi.org\/10.1080\/146608200300079536 (2000).","journal-title":"Amyotroph. Lateral Scler. Other Motor Neuron Disord."},{"key":"78390_CR37","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack, C. R. Jr et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018 (2018).","journal-title":"Alzheimers Dement."},{"key":"78390_CR38","doi-asserted-by":"publisher","unstructured":"Jack, C. R. Jr et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease. Alzheimers Dement. 20, 5143\u20135169 https:\/\/doi.org\/10.1002\/alz.13859 (2024).","DOI":"10.1002\/alz.13859"},{"key":"78390_CR39","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nrneurol.2014.184","volume":"10","author":"B Swinnen","year":"2014","unstructured":"Swinnen, B. & Robberecht, W. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 10, 661\u2013670 https:\/\/doi.org\/10.1038\/nrneurol.2014.184 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"78390_CR40","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00415-020-09761-z","volume":"267","author":"S Abu-Rumeileh","year":"2020","unstructured":"Abu-Rumeileh, S. et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers in amyotrophic lateral sclerosis. J. Neurol. 267, 1699\u20131708 https:\/\/doi.org\/10.1007\/s00415-020-09761-z (2020).","journal-title":"J. Neurol."},{"key":"78390_CR41","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/jnnp.2010.235952","volume":"82","author":"A Chi\u00f2","year":"2011","unstructured":"Chi\u00f2, A. et al. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population-based study. J. Neurol. Neurosurg. Psychiatry 82, 740\u2013746 https:\/\/doi.org\/10.1136\/jnnp.2010.235952 (2011).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"78390_CR42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/brain\/awr351","volume":"135","author":"JC Roche","year":"2012","unstructured":"Roche, J. C. et al. A proposed staging system for amyotrophic lateral sclerosis. Brain 135, 847\u2013852 https:\/\/doi.org\/10.1093\/brain\/awr351 (2012).","journal-title":"Brain"},{"key":"78390_CR43","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695\u2013699 https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x (2005).","journal-title":"J. Am. Geriatr. Soc."},{"key":"78390_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3109\/21678421.2013.805784","volume":"15","author":"S Abrahams","year":"2014","unstructured":"Abrahams, S. et al. Screening for cognition and behaviour changes in ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 9\u201314 https:\/\/doi.org\/10.3109\/21678421.2013.805784 (2014).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"78390_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13195-018-0448-x","volume":"10","author":"H Shahpasand-Kroner","year":"2018","unstructured":"Shahpasand-Kroner, H. et al. A two-step immunoassay for the simultaneous assessment of A\u03b238, A\u03b240 and A\u03b242 in human blood plasma supports the A\u03b242\/A\u03b240 ratio as a promising biomarker candidate of Alzheimer\u2019s disease. Alzheimers Res. Ther. 10, 121 https:\/\/doi.org\/10.1186\/s13195-018-0448-x (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"78390_CR46","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3233\/JAD-150859","volume":"51","author":"BN Dugger","year":"2016","unstructured":"Dugger, B. N. et al. The presence of select tau species in human peripheral tissues and their relation to Alzheimer\u2019s disease. J. Alzheimers Dis. 51, 345\u2013356 https:\/\/doi.org\/10.3233\/JAD-150859 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"78390_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2023.137330","volume":"810","author":"Y Hamsafar","year":"2023","unstructured":"Hamsafar, Y. et al. Biochemical analyses of tau and other neuronal markers in the submandibular gland and frontal cortex across stages of Alzheimer disease. Neurosci. Lett. 810, 137330 https:\/\/doi.org\/10.1016\/j.neulet.2023.137330 (2023).","journal-title":"Neurosci. Lett."},{"key":"78390_CR48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00401-024-02729-7","volume":"147","author":"MJ Ellis","year":"2024","unstructured":"Ellis, M. J. et al. Identification of high-performing antibodies for the reliable detection of tau proteoforms by Western blotting and immunohistochemistry. Acta Neuropathol. 147, 87 https:\/\/doi.org\/10.1007\/s00401-024-02729-7 (2024).","journal-title":"Acta Neuropathol."},{"key":"78390_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00401-025-02881-8","volume":"149","author":"T Kavanagh","year":"2025","unstructured":"Kavanagh, T. et al. The interactome of tau phosphorylated at T217 in Alzheimer\u2019s disease human brain tissue. Acta Neuropathol. 149, 44 https:\/\/doi.org\/10.1007\/s00401-025-02881-8 (2025).","journal-title":"Acta Neuropathol."},{"key":"78390_CR50","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","volume":"26","author":"B MacLean","year":"2010","unstructured":"MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966\u2013968 https:\/\/doi.org\/10.1093\/bioinformatics\/btq054 (2010).","journal-title":"Bioinformatics"},{"key":"78390_CR51","doi-asserted-by":"publisher","first-page":"D459","DOI":"10.1093\/nar\/gkaf1146","volume":"54","author":"EW Deutsch","year":"2026","unstructured":"Deutsch, E. W. et al. The ProteomeXchange consortium in 2026: making proteomics data FAIR. Nucleic Acids Res 54, D459\u2013D469 https:\/\/doi.org\/10.1093\/nar\/gkaf1146 (2026).","journal-title":"Nucleic Acids Res"},{"key":"78390_CR52","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","volume":"53","author":"Y Perez-Riverol","year":"2025","unstructured":"Perez-Riverol, Y. et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 53, D543\u2013D553 https:\/\/doi.org\/10.1093\/nar\/gkae1011 (2025).","journal-title":"Nucleic Acids Res."},{"key":"78390_CR53","doi-asserted-by":"publisher","unstructured":"Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 https:\/\/doi.org\/10.1038\/msb.2011.75 (2011).","DOI":"10.1038\/msb.2011.75"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-78390-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-78390-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-78390-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:02:41Z","timestamp":1792659761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-78390-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["78390"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-78390-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.A.R. is a\u00a0member of the editorial Board of Scientific Reports. A.Me. has received advisory board honoraria from Hormosan and Sanofi, speaking fees from Argenx, Amicus Therapeutics, and Sanofi, unrelated to the work presented in this paper. P.O. received consulting fees from LifeArc and Fundamental Pharma, honoraria for lectures from GSK and travel support from Biogen, all unrelated to the present work. J.W. has been an honorary speaker for Actelion, Amgen, Beijing Yibai Science and Technology Ltd., Janssen Cilag, Med Update GmbH, Pfizer, Roche Pharma, and has been a member of the advisory boards of Abbott, Biogen, Boehringer Ingelheim, Lilly, MSD Sharp & Dohme, and Roche Pharma and receives fees as a consultant for Immungenetics and Roboscreen, all unrelated to the present work. J.W. holds the following patents: PCT\/EP 2011 001724 and PCT\/EP 2015 052945, all unrelated to the present work. V.S. received compensation for consulting services and\/or speaking activities from AveXis, Cytokinetics, Italfarmaco, Liquidweb S.r.l., Novartis Pharma AG, Amylyx Pharmaceuticals, Biogen, and Zambon Biotech SA; V.S. is in the Editorial Board of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, European Neurology, American Journal of Neurodegenerative Diseases, Frontiers in Neurology, and Exploration of Neuroprotective Therapy. N.T. received compensation for consulting services\/speaking fees from Amylyx Pharmaceutical, Biogen, Eli Lilly, Italfarmaco, Lundbeck and Zambon Biotech SA, all unrelated to the present work; N.T. is associate editor of Frontiers in Aging Neuroscience and member of the Editorial Board of Neurological Sciences. L.F. has received grants, consultancy fees, or lecture honoraria from Biogen, Eisai, Grifols, Hummingbird, InfectoPharm, Janssen-Cilag, Merck Sharpe & Dohme, Neurimmune, Neuromodulation, Noselab, Novo Nordisk, Roche, TauRX, and Schwabe; has served on Data and Safety Monitoring boards with Otsuka, Pharmatrophix, Forschungszentrum J\u00fclich, Charit\u00e9 Berlin, Neuroscios, and Vivoryon, unrelated to the present work; L.H. made consulting services for Lilly and EISAI in 2025, unrelated to the work presented in this paper. D.R.T. received consultant honoraria from Muna Therapeutics (Denmark) and collaborated with Novartis Pharma (Switzerland), GE-Healthcare (UK), and ADx Neurosciences (Belgium), unrelated to the work presented in this paper. M.O. received consulting fees from Biogen, Axon, Roche, and Grifols; and participates on the Biogen ATLAS trial board, all unrelated to the work presented in this paper; is a speaker of the German FTLD consortium, is involved in an unpaid role with the German Society for CSF Diagnostics and Neurochemistry. M.O. and P.O. are co-inventors of a patent application for using beta-synuclein measurement in blood. I.L. and D.O. are employees of Roboscreen GmbH, Leipzig, Germany. The other authors report no disclosures relevant to the manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10745"}}